Shareholders backed the Korsana merger share issuance and change of control on August 26, 2026. The combined company expects to trade on Nasdaq as KRSA from September 9, 2026; a Cayman redomestication failed.
Cyclerion and private Korsana Biosciences signed a merger agreement on April 1, 2026. A concurrent private financing of approximately $380 million is expected to fund Korsana's operations into 2029.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.4 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Korsana Biosciences
Did Korsana Biosciences do a reverse stock split?
Our latest story on this, dated Aug 27, 2026: "Cyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split". The story links the filing or release it is based on. Read the story.
Has Korsana Biosciences raised money recently?
Our latest story on this, dated May 7, 2025: "Cyclerion Therapeutics (now Korsana Biosciences) sets up ATM program with Guggenheim". The story links the filing or release it is based on. Read the story.
Is Korsana Biosciences involved in a merger or acquisition?
Our latest story on this, dated Aug 27, 2026: "Cyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Korsana Biosciences?
Korsana Biosciences, Inc. trades under the ticker KRSA on NASDAQ.
Where is Korsana Biosciences listed?
Korsana Biosciences, Inc. is listed on NASDAQ.
What is the SEC CIK of Korsana Biosciences?
The SEC Central Index Key (CIK) for Korsana Biosciences, Inc. is 1755237. Its filings are on SEC EDGAR.
How many shares does Korsana Biosciences have outstanding?
4,681,351 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Korsana Biosciences listed under?
Our directory records Korsana Biosciences, Inc. under United States.
What does Korsana Biosciences do?
Our directory classifies Korsana Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Korsana Biosciences?
The ISIN recorded for Korsana Biosciences, Inc. is US23255M3034.
Does aibio.space cover Korsana Biosciences?
aibio.space lists Korsana Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Korsana Biosciences incorporated?
SEC records list its state or country of incorporation as MA.
What was Korsana Biosciences's revenue last year?
$2.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Korsana Biosciences profitable?
Korsana Biosciences, Inc. reported a net loss of $3.5 million for the fiscal year ended Dec 31, 2025, and used $3.3 million of cash in operations, per its annual report to the SEC.
How much does Korsana Biosciences spend on research and development?
$959,000 in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Korsana Biosciences
Members talk about Korsana Biosciences (KRSA). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Korsana Biosciences, newest first. Each line links the filing it comes from.
Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Mergers
Reported a merger or acquisition agreement. SEC Form 425. Source
Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,7.01,9.01). Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:KRSA on TradingView.
SEC filings and registration
SEC name
Korsana Biosciences, Inc.
CIK
1755237
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
KRSA (Nasdaq)
State or country of incorporation
MA
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
203 CRESCENT STREET, WALTHAM, MA, 02453
Phone
(781) 516-2325
Shares outstanding
4,681,351 as of 2026-08-04 (10-Q filed 2026-08-04)
Former names
Cyclerion Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Korsana Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KRSA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio